Aquestive Therapeutics (NASDAQ:AQST) is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S. Food and Drug Administration for the acute treatment of seizure clusters in patients with epilepsy. In addition to internally developed assets, Aquestive licenses its PharmFilm platform to third parties, supporting products such as Nexafed® (pseudoephedrine) and Vazalore® (aspirin), both of which incorporate abuse‐deterrent or gastrointestinal safety features.
Aquestive maintains a robust development pipeline, including Qtrypta™ (sumatriptan) for the acute treatment of migraine, which is in late‐stage regulatory review. The company’s research activities also span novel formulations in pain management, central nervous system disorders and other therapeutic areas where film technology can enhance drug delivery characteristics.
Originally founded as MonoSol Rx in 2004, the company rebranded as Aquestive Therapeutics in 2018 to reflect its broader strategic focus. Headquartered in Warren, New Jersey, Aquestive operates facilities for research, development and manufacturing in the United States. Under the leadership of President and Chief Executive Officer Albert J. “Al” Altomari, the company continues to pursue commercial growth and expansion of its PharmFilm platform globally.
